DURECT Corporation (NASDAQ:DRRX) continues to move higher and up almost 8% in just one week. Will the rally continue?
As of 10:32, DRRX stock jumped by 2.87% at $1.79. The stock has traded 244K shares, compared to its average volume of 848K shares. The stock opened at $1.75 and moved in a range of $1.7500 – 1.8450.
DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)
- announced it will present two posters at the 2021 International Liver Conference (EASL) to be held virtually June 23-26, 2021.
- The first poster will discuss additional efficacy signals from a Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis (NASH) patients. Previously reported data showed that DUR-928 was well tolerated at all three doses evaluated, 50mg QD, 150mg QD, and 300mg BID (600mg/day) with overall improvement from baseline observed in liver enzymes, serum lipid profiles, liver fat by imaging, and biomarkers of liver health. The poster will feature additional efficacy signal data including liver stiffness by transient elastography (TE) and magnetic resonance elastography (MRE), liver fibrosis marker, pro-C3, and ELF scores, as well as insulin resistance (HOMA-IR).
- A second poster will provide data from a Phase 1 study assessing the safety, tolerability, pharmacokinetics (PK) of DUR-928 in subjects with moderate (Child-Pugh B scores) and severe (Child-Pugh C scores) hepatic impairment (HI), who received a single oral dose of 200mg DUR-928.